Analysts at Zacks downgraded shares of Zoetis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 2nd. They now have a $27.00 price target on the stock. Finally, analysts at William Blair upgraded shares of Zoetis from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 12th. Zoetis Inc (NYSE:ZTS) shares after opening at $28.48 moved to $28.78 on last trade day and at the end of the day closed at $28.48. Company price to sales ratio in past twelve months was calculated as 3.13 and price to cash ratio as 23.38. Zoetis Inc (NYSE:ZTS) showed a negative weekly performance of -1.79%.
Antares Pharma Inc (NASDAQ:ATRS) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Antares Pharma develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. Antares Pharma Inc (NASDAQ:ATRS) shares fell -1.32% in last trading session and ended the day on $2.99. ATRS return on equity ratio is recorded as -26.70% and its return on assets is -23.10%.Antares Pharma Inc (NASDAQ:ATRS) yearly performance is -14.08%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) reported a loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents, but wider than the year-ago loss of 1 cent per share. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares moved up 2.02% in last trading session and was closed at $3.53, while trading in range of $ 3.40 – 3.70. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) year to date (YTD) performance is -33.77%.
ImmunoGen, Inc. (NASDAQ:IMGN) has with this initial success posted good pipeline of product. In addition to IMGN853, it will also look at IMGN529, which is a non-Hodgkin Lymphoma. Other drugs include IMGN289, which includes treatment for other forms of cancer. Immuno Gen, Inc. (NASDAQ:IMGN) weekly performance is -6.24%. On last trading day company shares ended up $12.78. Immuno Gen, Inc. (NASDAQ:IMGN) distance from 50-day simple moving average (SMA50) is -17.94%. Analysts mean target price for the company is $16.95.